E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.

Title:	E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.
Authors:	Claudiani, S Apperley, J Gale, RP Clark, R Szydlo, R Deplano, S Palanicawandar, R Khorashad, J Foroni, L Milojkovic, D
Item Type:	Journal Article
Issue Date:	11-May-2017
Date of Acceptance:	1-May-2017
URI:	http://hdl.handle.net/10044/1/49044
DOI:	https://dx.doi.org/10.3324/haematol.2017.168740
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Start Page:	e297
End Page:	e299
Journal / Book Title:	Haematologica
Volume:	102
Issue:	8
Copyright Statement:	© 2017 Ferrata Storti Foundation. Haematologica August 2017 102: e297-e299; Doi:10.3324/haematol.2017.168740. Open Access under the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/)
Sponsor/Funder:	Imperial College Trust Imperial College Healthcare NHS Trust- BRC Funding National Institute for Health Research Imperial College Healthcare NHS Trust
Funder's Grant Number:	070904JA RDB05 79560 NF-SI-0611-10275 IPH-RMO-HH/004
Keywords:	Chronic Myelogenous Leukemia Chronic Myeloproliferative Disorders Minimal Residual Disease Stopping TKI Treatment free remission Immunology 1102 Cardiovascular Medicine And Haematology
Publication Status:	Published
Conference Place:	Italy
Appears in Collections:	Department of Medicine (up to 2019)